document incorporate reference specify portion registrant definitive proxy statement file commission pursuant regulation connection annual meeting incorporate reference iii report base closing price share exclude share registrant common stock hold executive officer director stockholder ownership exceed common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrant september registrant implement twoforone stock split form stock dividend share share amount period present restate reflect stock split gilead sciences inc annual report table content item business item property item legal proceeding item submission matter vote security holder ii item market registrant common equity relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iiiitem director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead science hepsera viread vistide daunoxome ambisome emtriva truvada macugen registered trademark belong eyetech pharmaceuticals inc sustiva register trademark bristolmyer squibb company tamiflu register trademark belong hoffmannla roche report include trademark service mark trade name company item business forwardlooke statement risk factor report include forwardlooke statement particular statement expectation belief plan objective assumption future event performance contain incorporate reference report base forwardlooke statement current expectation future event believe expectation reasonable forwardlooke statement inherently subject risk uncertainty control actual result differ materially suggest forwardlooke statement reason include discuss report head risk factor affect gilead beginning give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof undertake specifically decline obligation update statement publicly announce result revision forward look statement reflect future event development report indicate refer gilead subsidiary overview gilead sciences inc biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease multinational company approve product focus research clinical program antiinfective seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy worldwide headquarters foster city california european headquarters paris france incorporate delaware june product viread oral formulation nucleotide analogue reverse transcriptase inhibitor dose day combination therapy treat human immunodeficiency virus hiv infection adult sell viread united states commercial team wholesaler major european country european commercial team distributor japan corporate partner japan tobacco exclusive worldwide license patent right relate technology viread institute organic chemistry biochemistry academy sciences czech republic rega stichting vzw iocbrega emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult sell emtriva united states commercial team wholesaler major european country european commercial team distributor exclusive worldwide license patent right relate technology emtriva emory university truvada oral tablet dose day combination therapy treat hiv infection adult fixeddose combination antihiv medication emtriva viread truvada combine mg emtricitabine emtriva mg tenofovir disoproxil fumarate viread truvada currently sell united states commercial team wholesaler international commercial team begin launch truvada european union follow recent regulatory approval february exclusive worldwide license patent right relate technology component truvada iocbrega emory university ambisome proprietary liposomal formulation amphotericin b powerful antifungal agent treat invasive fungal infection cause fungal specie deliver amphotericin b proprietary liposomal formulation ambisome reduce rate severity kidney toxicity injectionrelate reaction associate amphotericin b allow patient receive high dose amphotericin b ambisome approve sale country include united states countries european union country ambisome approve include united states authorize promote ambisome empirical treatment fungal infection treatment patient strong suspicion definite confirmation exist potentially lifethreatene invasive fungal infection remain country ambisome approve use firstline treatment invasive fungal infection secondline treatment conventional amphotericin b therapy fail conventional amphotericin b tolerate market ambisome major country europe copromote ambisome united states fujisawa healthcare inc fujisawa hepsera oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dose day treat chronic hepatitis b hepsera approve sale united states treatment chronic hepatitis b adult evidence active viral replication evidence persistent elevation serum aminotransferase alt ast histologically active liver disease commercial team wholesaler sell hepsera united states sell hepsera major european union country european commercial team distributor license right commercialize hepsera solely treatment hepatitis b china japan korea taiwan rest asia latin america certainother territories glaxosmithkline gsk launch hepsera japan south korea taiwan exclusive worldwide license patent right relate technology adefovir dipivoxil iocbrega vistide antiviral medication treatment cytomegalovirus cmv retinitis patient aid cmv retinitis condition characterize lesion form patient retina affect person weaken immune system common patient aid vistide approve sale sell united states commercial team gilead exus partner pfizer inc pfizer pharmacia corporation country treatment cmv retinitis patient aid daunoxome liposomal formulation anticancer agent daunorubicin approve sale sell country treatment aidsrelate kaposis sarcoma sell united states commercial team independent distributor abroad december decide discontinue selling product subsequently receive unanticipated request europe reconsider sell daunoxome continue sell product limited number country currently evaluate supply sale strategy regard product royalty source macugen antiangiogenic injection treatment neovascular agerelate macular degeneration amd drug inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease macugen approve fda united states december begin sell january product approve outside united states macugen develop eyetech pharmaceuticals inc eyetech technology license eyetech hold exclusive right manufacture sell macugen worldwide subject eyetechs obligation pay percentage net revenue eyetech generate macugen sale patent technology license eyetech expire united states europe tamiflu oral pill treatment prevention influenza b tamiflu class prescription drug call neuraminidase inhibitor tamiflu approve country include united states japan countries european union treatment influenza child adult tamiflu approve united states european union prevention influenza adolescent adult develop tamiflu f hoffmannlaroche ltd roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale subject reduction certain define manufacturing cost follow table list aggregate product sale major product thousand product product product sale sale sale viread emtriva truvada total hiv product ambisome total product sale note consolidated financial statement financial information geographic area product market product clinical trial research development seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy acquisition triangle pharmaceuticals inc complete january research scientist foster city san dimas california durham north carolina engage discovery development new molecule technology hope lead new medicine novel formulation exist drug therapeutic focus area life threaten infectious disease research include work proprietary nucleotide analogue develop treatment viral infection particularly hiv hepatitis c infection total research development rd expense million compare million million research effort area hepatitis c viral infection hcv include collaboration chiron corporation chiron genelabs technologies genelabs achillion pharmaceuticals inc achillion august enter agreement chiron research develop commercialize small molecule therapeutic certain hcv drug target october enter research development agreement genelabs technologies genelabs discover develop commercialize nucleoside rna polymerase inhibitor treatment hcv infection november enter research development agreement achillion discover commercialize novel inhibitor hcv replication addition inhouse program design discover small molecule inhibitor hcv rna polymerase hcv protease believe small molecule therapeutic treatment hcv infection day lead well treatment outcome patient program require extensive investment year note consolidated financial statement discussion commercial operation international commercial sale operation marketing subsidiary australia canada france germany greece ireland italy new zealand portugal spain united kingdom commercial team promote hiv hbv product viread emtriva truvada hepsera direct field contact physician hospital clinicsand healthcare provider involve treatment patient hiv hiv product chronic hepatitis b hepsera team promote ambisome infectious disease specialist hematologist intensive care unit hospital home health care provider cancer specialist country outside united states agreement thirdparty distributor include distributor certain country market operation promote sell distribute product international distribution agreement generally provide distributor exclusive right sell product particular country country specify period time december announce program pursuant sell viread cost country africa country designate develop united nations expand program august include truvada take step ensure viread truvada product sell program serve patient develop world divert market international distribution collaborative relationship business strategy establish collaboration company assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company description accounting relationship find note consolidated financial statement include report follow list representative collaborative relationship collaborator program area year signing bristolmyer squibb hiv achillion hcv genelab hcv japan tobacco hiv glaxosmithkline hepsera archemix selex technology eyetech macugen roche tamiflu pfizer vistide fujisawa ambisome bristolmyers squibb company december enter collaboration agreement bristolmyer squibb company bm develop commercialize fixeddose combination gilead truvada bmss sustiva efavirenz united states structure joint venture gilead bms form limited liability company bristolmyers squibb gilead sciences llc approve new product complete highly active antiretroviral therapy haart treatment regimen hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider joint venture company work partnership complete development regulatory filing fixeddose regimen subject receive marketing approval fixeddose regimen company share responsibility commercialize product united states company provide fund fieldbased sale representative support promotional effort combination product term collaboration gilead bms grant royaltyfree sublicense joint venture use respective companyowne technology return grant license use jointly create intellectual property gilead bms ownership interest joint venture reflect respective economic interest base fraction net selling price fixeddose combination product attributable truvada sustiva respectively adjust annual basis net selling price truvada change time relative net selling price sustiva joint venturer respective economic interest joint venture vary annually academic consulting relationship supplement research development effort regular business enter arrangement university medical research institution arrangement provide right patent patent application technology own institution return payment fee relate use right emory university university georgia research foundation inc emtricitabine april triangle obtain january acquire acquisition triangle exclusive worldwide license emory universitys right purify form emtricitabine use hiv hbv field obligate certain milestone royalty payment emory include annual minimum royalty begin year fda registration grant antihiv product incorporate emtricitabine technology united states year registration grant antihbv product incorporate emtricitabine technology certain major market country hiv hbv indication respectively triangle begin pay license maintenance fee development milestone achieve emory gsk settle litigation pende united states district court relate emtricitabine exclusive licensee foreign patent patent application file burrough wellcome co use emtricitabine treat hepatitis b settlement agreement obligate pay royalty gsk net sale product contain emtricitabine addition emory receive access development clinical datum drug substance hold gsk relate emtricitabine emory gsk shire pharmaceuticals group plc shire settle worldwide patent dispute involve lamivudine emtricitabine term settlement emory receive exclusive license shire shire patent relate emtricitabine method use manufacture shire gsk receive exclusive license emorys patent relate lamivudine term license agreement emory automatically acquire exclusive sublicense shire patent relate emtricitabine grant term settlement resolve previously pende patent dispute emtricitabine md anderson cancer centerin enter agreement md anderson cancer center relate hepsera agreement currently pay md anderson cancer center percentage net revenue base sale hepsera agreement md anderson cancer center terminate later patent expiration year commercial sale iocbrega enter agreement iocbrega relate viread hepsera vistide subsequently amend agreement include truvada agreement receive iocbrega exclusive right manufacture use sell nucleotide compound cover agreement agreement pay percentage net revenue base sale viread truvada hepsera vistide iocbrega agreement iocbrega terminate individual country basis later patent expiration year commercial sale addition iocbrega terminate license particular product key market absence commercial sale product month regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation technology hold company university colorado boulder relate selex technology identify aptamer arrangement ulehi grant present future right invention cover patent patent application selex technology improvement selex technology make discover oligonucleotide molecule make selex technology computer software relate selex technology require pay ulehi certain variable royalty base revenue generate sale product derive selex technology include revenue base license agreement eyetech relate macugen develop world collaboration bill melinda gates foundation family health international october enter agreement bill melinda gates foundation family health international fhi provide viread fhis multinational clinical trial evaluate viread effectiveness method reduce risk hiv infection sexually active adult regularly expose hiv clinical trial conduct fhi fund million threeyear grant gates foundation dart study november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conduct mrc antiretroviral hiv therapy africa trial call dart trial development antiretroviral therapy africa aim study clinical versus laboratory monitoring practice structure treatment interruption versus continuous antiretroviral therapy adult hiv infection subsaharan africa agree provide viread cost dart study institute world health january enter agreement institute world health pursuant provide ambisome cost phase clinical trial evaluate ambisome treatment visceral leishmaniasis paromomycin india great global burden visceral leishmaniasis clinical trial conduct institute world health partnership world health organization international distribution agreement distributor europe asia latin america middle east africa grant distributor exclusive right sell viread emtriva hepsera ambisome daunoxome particular country country specify period time agreement provide collaborative effort distributor obtain regulatory approval product particular country marketing product country agreement establish price distributor pay product require deliver quantity product order distributor manufacture ambisome manufacture ambisome commercial quantity separate adjacent facility san dimas california medicines control agency united kingdom fda approve commercial production ambisome facility produce import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union use commercially available material equipment manufacture product currently obtain amphotericin b cholesterol use manufacture ambisome single approve supplier ambisome sell freezedrie product currently freezedry ambisome san dimas manufacturing facility use party freezedry additional product need give current projection ambisome demand believe sufficient capacity meet future demand option instal additional freezedrying capacity san dimas additional supply necessary unable install additional freeze drying capacity san dimas locate appropriate party meet need ability meet increase ambisome demand diminish macugen manufacture macugen commercial quantity fda approve facilities san dimas california manufacturing agreement eyetech use commercially available material equipment manufacture product currently eyetech provide raw material manufacture macugen include pegaptanib sodium active ingredient macugen single approve supplier contract eyetech manufacturing process currently produce fill macugen san dimas manufacturing facility give eyetechs current projection macugen demand believe sufficient capacity meet future demand option instal additional production filling capacity san dimas additional supply necessary unable install additional production filling capacity san dimas locate appropriate party meet need ability meet increase macugen demand diminish macugen sell liquid form fill syrinx san dimas facility syrinx supply single approve supplier contract eyetech antiviral product contract party manufacture antiviral drug clinical commercial purpose include viread emtriva truvada hepsera vistide manufacture tenofovir disoproxil fumarate bulk drug substance contract manufacturer viread tablet manufacture contract manufacturer manufacture emtricitabine bulk drug substance contract manufacturer emtriva tablet manufacture contract manufacturer second contract manufacturer currently qualified manufacture truvada tablet single contract manufacturer united states second contract manufacturer currently qualify obtain qualification united states european union contract manufacturer adefovir dipivoxil bulk drug substance contract manufacturer hepsera tablet commercial supply europe contract manufacturer qualified commercial supply united states second currently qualified supplier approve fda european union manufacture cidofovir bulk drug substance vistide single fda emea approve supplier vistide drug product roche responsible manufacturing tamiflu january roche announce production problem liquid suspension form tamiflu approve treatment child young yearold available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem november chugai announce recall tamiflu result reduce net sale royalty roche royalty income tamiflu net sale increase substantially primarily severe flu season united states late commercialscale manufacturing facility antiviral product future antiviral product need develop additional manufacturing capability establish additional party supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct largescale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product compound proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product compound agreement manufacturer intend restrict reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture product compound require enter agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable believe compliance material environmental regulation relate manufacture product patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show actual estimate expiration date united states europe primary patent patent issue pende application cover compound market product product candidate product patent expiration european patent expiration vistide hepsera ambisome tamiflu viread emtriva truvada patent cover viread hepsera vistide emtriva truvada hold party acquire exclusive right patent agreement party collaborative relationship academic consulting relationship patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret patent filing cover form hepsera china certain asian country application pende asian country include china relate specific form formulation hepsera asia major market hbv therapy obtain patent compound year obtain marketing approval patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent vistide grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain themit important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license adversely affect patent application confidential period time include united states patent issue pende patent application patent eventually issue prevent develop sell certain product obtain license use patent technology patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection addition pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop develop addition certain country permit enforcement patent manufacturer able sell generic version product country rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention competition product development program target number disease condition include viral fungal infection commercially available product disease large number company institution spend considerable amount money resource develop additional product treat disease current product compete available product base primarily efficacy safety tolerability acceptance doctor patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability mode dose product market future compete product offer competitor competitor introduce datum improve characteristic product improve increase marketing effort simply low price product sale product decrease certain product develop future compare favorably product offer competitor exist future product compare favorably new product develop competitor ability competitive depend ability attract retain qualified personnel obtain patent protection develop proprietary product process secure sufficient capital resource substantial period take develop product hiv product hiv competitive landscape crowd complicated treatment trend continue evolve grow number antihiv drug currently sell advanced stage clinical development twentysix brand drug available united states zerit stavudine dt sell bristolmyer squibb bms fix combination product combivir azt tc trizivir azt tc abc sell gsk represent direct competition hiv product company process launch formulation exist drug indicate fda daily oral dosing include gsk mg dose epivir lamivudine tc recently approve antiretroviral product include epzicom fix dose combination ziagen epivir gsk approve united states european union fuzeon injectable integrase inhibitor rochetrimeris reyataz atazanivir sulfate onceaday protease inhibitor bms tipranavir nonpeptidic protease inhibitor boehringeringelheim gsk file application approval oncedaily dose ziagen abacavir sulfate company compete hiv therapeutic category pfizer merck abbott bmss videx ec didanosine generic hiv product united states gsk retrovir azt expect face generic competition early united states effect overall market hiv product unknown price decrease hiv product result ambisome ambisome face strong competition current expect competitor current competitor include conventional amphotericin b bms numerous generic manufacturer caspofungin product develop merck market cancidas united states caspofungin voriconazole develop pfizer market vfend lipidbase amphotericin b product approve sale united states europe include abelcet sell enzon corp united states canada japan medeus pharma ltd europe amphotec sell intermune pharmaceutical inc presently unapproved expect competitor include class treatment call echinocandin include fujisawa micafungin receive marketing approval japan october review regulatory approval united states canada anidulafungin vicuron inc versicor inc product candidate evaluate multiple latestage clinical trial finally schere plough develop noxafil posaconazole currently phase trial competition current expect competitor erode likely continue erode revenue receive sale ambisome hepsera hepsera face significant competition exist expect therapy treat patient infect hbv significantly entecavir oral nucleoside analogue develop bms expect launch late daily oral antiviral bms file approval fda prescription drug user fee act pdufa action date april epivirhbv lamivudine develop gsk collaboration shire pharmaceutical sell major country north south america europe asia orally administer nucleoside analogue inhibit hbv dna polymerase introna interferon alfab sell schere plough major country north south america europe asia introna injectable drug immunomodulatory effect hepsera face competition clinicalstage candidate include idenixs ldt oral nucleoside analogue currently phase trial roche pegasys pegylate interferon alfaa expect approve chronic hepatitis b united states late tamiflu tamiflu competes relenza antiflu drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine oral tablet inhibit replication influenza virus rimantadine oral antiviral vistide vistide compete number drug treat cmv retinitis include ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valganciclovir market roche foscarnet intravenous drug sell astrazeneca formivirsen drug inject directly eye sell cibavision number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently biopharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program anticipate face increase competition future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover money resource develop product government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug potential safety benefit submit datum fda investigational new drug application ind seek approval test compound human clinical trial fda accept investigational new drug application study drug human clinical trial determine drug safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug give small number healthy human subject patient test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug give limited patient population determine effect drug treating disease well dose drug possible effect safety risk drug phase compound appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug uncommon drug appear promise phase clinical trial fail rigorous reliable phase clinical trial fda approval process believe datum phase clinical trial adequate level safety effectiveness file new drug application nda thefda seek approval sell drug particular use fda review nda hold public hear independent advisory committee expert advisor ask additional question drug committee make recommendation fda bind fda generally follow fda fda agree compound meet require level safety effectiveness particular use allow sell drug united states use unusual fda reject application believe drug safe effective believe datum submit reliable conclusive point process development drug stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require complete additional testing provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine new drug application contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include san dimas facility foster city facility license state california compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug designate fast track product fda eligible accelerate sixmonth review accelerate approval case viread truvada drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe procedure decentralized system approval country european union obtain approval country european union simplify application process approval centralized procedure pricing reimbursement approval require country vistide viread hepsera emtriva february truvada approve european union centralize procedure viread hiv drug review accelerate approval european union hepsera receive traditional review emtriva march apply marketing application truvada treatment hiv european union begin european launch truvada follow regulatory approval receive february pricing reimbursement insurance company health maintenance organization hmos thirdparty payor federal state government seek limit charge drug example certain foreign market pricing negotiation require obtain approval product united states expect continue number federal state proposal implement drug price control addition manage care organization common united state continue seek low drug price announcement proposal effort cause stock price decrease proposal adopt revenue decrease ability sell drug depend availability reimbursement government private insurance company government insurance company demand rebate predetermine discount list price expect product develop particularly hivaid indication subject reimbursement issue certain product obtain regulatory approval reimburse government insurance company regulatory approval price require foreign country certain country condition approval product agreement seller sell product certain price country past require price reduction connection product approval certain foreign country require price approve product reduce product market period time certain regulatory authority future establish low price regulatory action reduce price product country practical effect require reduce price country european government notably germany italy implement consider legislation require pharmaceutical company sell product subject reimbursement mandatory discount mandatory discount reduce revenue receive drug sale certain develop country significantly affect hiv aids parallel import generic competition occur adversely affect revenue sale market share viread addition government regulatory action disallow pricing combination product truvada sum price component drug market particular country employee february approximately fulltime employee believe good relation employee website website address wwwgileadcom available free charge website annual report quarterly report form q current report form k director officer section report require sec filing amendment report soon reasonably practicable filing provide hyperlink edgar website contain report risk factor affect gilead evaluate business carefully consider follow risk addition information report follow risk couldmaterially adversely affect business operating result financial condition substantially revenue derive sale limited number product unable maintain continue grow sale hiv product maintain sale ambisome result operation adversely affect currently dependent sale hiv product especially viread ambisome support exist operation viread comprise hiv product sale important consider viread emtriva truvada collectively future sale product intimately tie sale hiv product ambisome account approximately total product revenue year end december unable continue grow hiv product revenue maintain ambisome sale result operation likely suffer need scale operation hiv product sale year end december million total revenue ambisome product sale royalty year end december million total revenue able continue growth rate sale hiv product current sale level ambisome reason state risk factor section particular follow reason face significant competition business substantially great resource merck pfizer release new product compete ambisome glaxosmithkline market fixeddose combination product compete truvada competitor product operate field compete long ambisome sale volume relatively flat compare hiv product ambisome long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning label narrow approve indication halt sale product reduce revenue product mature private insurer government reimburser reduce reimburse patient product increase pressure reduce price large market hiv product patient take hiv drug successful encourage physician change patient prescription hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing affect fail commercialize new product expand indication exist product prospect future revenue stock price adversely affect introduce new product increase revenue exist product able grow revenue fail increase sale hiv product able increase revenue expand research development effort successful effort collaboration bristol myers squibb company formulate onceaday pill combination truvada sustiva failure achieve objective expect material adverse effect business result operation significant safety issue arise market product sale decline adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case limit postapproval use component truvada emtriva viread study individually safety efficacy study truvada ongoing follow approval product long period time patient take numerous medicine underlie health problem monitor dose compliance drug long period time patient find expect continue find new issue safety resistance drug interaction issue require provide additional warning label narrow approve indication reduce market acceptance product safety resistance interaction issue arise market product sale product limit halt regulatory authority operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda comparable regulatory agency country continue clinical trial ambisome viread hepsera emtriva truvada currently approve additional use anticipate file marketing approval additional country additional product year product fail receive marketing approval timely basis addition market product manufacture sell product subject extensive continue regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution recently formation independent drug safety office announce tasked monitoring safety approve product new office increase difficulty length time require new drug obtain marketing approval office create postapproval obligation require comply result clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety effectiveness product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product development fail achieve primary endpoint clinical trial safety issue arise commercialization drug candidate delay halt addition clinical trial involve commercial product raise new safety issue exist product reduce revenue manufacturing problem delay product shipment regulatory approval adversely affect result operation depend party perform manufacturing activity effectively timely basis party fail perform require impair ability deliver product timely basis cause delay clinical trial application regulatory approval event harmour competitive position manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation manufacturer subject fda current good manufacturing practice extensive regulation govern manufacturing process stability testing recordkeeping quality standard similar regulation effect country addition manufacturing operation subject routine inspection regulatory agency viread hepsera vistide emtriva truvada rely party manufacture bulk drug substance final drug product clinical commercial purpose addition roche responsible manufacturing tamiflu thirdparty manufacturer develop problem control problem adversely affect business example january roche announce production problem liquid suspension form tamiflu approve treatment child young year old available japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale tamiflu royalty roche manufacture ambisome facility san dimas california formulation manufacturing facilities united states manufacturing facility ireland conduct quality control testing labeling packaging addition use party alternate contract supplier fill freeze dry certain batch product event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need able obtain material necessary manufacture product limit ability generate revenue material utilize operation facility example depend single supplier high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol manufacture liposomal product supplier key component material name new drug application file fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship viread ambisome hepsera emtriva truvada vistide supply product development clinical trial depend relationship company sale marketing performance revenue failure maintain relationship negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance include collaboration fujisawa sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide japan tobacco viread emtriva truvada recently announce joint venture bristolmyer squibb develop commercialize fixeddose combination truvada sustiva certain country rely international distributor sale ambisome viread emtriva european country intend rely international distributor sale hepsera relationship involve clinical development product partner reliance collaborative relationship pose number risk include able control corporate partner devote sufficient resource program product dispute arise future respect ownership right technology develop corporate partner disagreement corporate partner lead delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue exist product decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan korea success hepsera territory depend entirely effort gsk regard gsk promote epivirhbv product compete hepsera consequently gsk marketing strategy hepsera influence promotion epivirhbv receive royalty gsk equal percentage gsk net sale hepsera net sale gsk epivirhbv gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera substantially reduce expense associate clinical trial sale fluctuation result inventory level hold wholesaler cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval extremely expensive difficult accurately predict control timing expense uneven unexpected spending program cause operating result fluctuate quarter quarter addition approximately product sale united states distributor amerisourcebergen corp cardinal health inc mckesson corp inventory level hold wholesaler fluctuate significantly cause sale result operating result fluctuate unexpectedly quarter quarter example base review ndc health corp prescription trend ims health inc inventory datum actual viread sale believe quarter end june wholesaler build inventory level estimate month believe inventory buildup follow equivalent possibly great inventory reduction quarter end september know inventory management agreement enter year major wholesaler continue effective match inventory level end user demand rely wholesaler estimate end user demand approximately half product sale occur outside united states currency fluctuation cause earning fluctuate adversely affect stock pricea significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar equivalent sale negatively impact financial condition result operation use foreign currency forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collected additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable use forward contract reduce impact foreign currency fluctuation future result effort successful fluctuation adversely affect result operation face credit risk european customer adversely affect result operation particularly subject credit risk european customer european product sale government own support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice account receivable government own support customer country total million december significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect plan supply viread truvada cost certain develop country expose liability material adverse affect result operation financial condition launch distribution program pursuant supply viread truvada cost countries africa country designate develop united nations supply distribution drug resourcepoor environment complicated undertaking program develop face unforeseen challenge risk rise unforeseen liability example patient develop country viread truvada closely supervise doctor develop nation accordingly increase likelihood viread truvadarelate complication go undetected untreated result significant liability gilead product revenue reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly viread truvada agree provide cost country africa country designate develop country united nations revenue adversely affect addition european union require permit cross border sale allow buyer country governmentapprove price product relatively high purchase product legally country sell low price additionally consumer able purchase product include hiv medicine internet pharmacy country substantial discount crossborder sale adversely affect revenue country require grant compulsory license hiv product face generic competition hiv product number develop country government official group suggest pharmaceutical company drug hiv infection available low cost alternatively government country require grant compulsory license allow competitor manufacture sell version product reduce sale certain country permit enforcement patent manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale ambisome vistide significant percentage sale viread hepsera subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase international pricing pressure pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general europe success hepsera tamiflu emtriva viread truvada depend largely obtain maintain government reimbursement european country include united kingdom france patient use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month expect success product development particularly europe depend ability obtain reimbursement reimbursement available reimbursement policy adversely affect ability sell product profitable basis example europe international market government control price prescription pharmaceutical expect price prescription pharmaceutical decline life product volume increase previous year see significant price decrease product europe believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth result operation adversely affect future health care reform unite states recent year new legislation propose federal state level effect major change health care system nationally state level proposal include prescription drug benefit proposal medicare beneficiary recently pass congress additionally state enact health care reform legislation federal state development possible impact propose legislation reform unclear result pricing reimbursement restriction adversely impact revenueswe able obtain effective patent protect technology use competitor patent company require stop pay use require technology success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right number foreign patent patent application right patent relate compound product technology risk issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time united states patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension addition patent provide adequate protection certain country africa asia include china competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful approval process product fda determine product grant exclusivity period manufacturer application approval generic version product grant generic manufacture wait challenge patent protect product grant exclusivity year prior end exclusivity period near end exclusivity period grant product patent subject challenge need spend significant resource defend able defend patent successfully success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company maintain product liability insurance successful product liability claim cover insurance require pay amount provide insurance impair financial condition ability clinically test market product expensive litigation reduce earning name defendant number lawsuit use average wholesale price reimbursement rate medicaid name lawsuit allege violation federal security law adverse result lawsuit result material damage significantly reduce earning cash flow change effective income tax rate reduce earning factor favorable unfavorable effect effective income tax rate factor include limited interpretation exist tax law change tax law rate future level research development spending change accounting rule future level capital expenditure changes mix earning tax jurisdiction operate change overall level pretax earning impact income tax provision result abovementione factor significant negative impact result operation recently adopt change account stock option affect earning financial accounting standard board fasb recently issue statement financial accounting standard revise sharebased payment sfas r require implement quarter provide new guidance accounting stock option new accounting guidance require record additional compensation expense relate stock option equity incentive currently evaluate option valuation methodology include blackschole method binomial method method allow fas r impact earning result new standard significant negative impact result operation item property corporate headquarters include principal executive office research facility locate foster city california location approximately square foot space proximately locate building currently occupy building tenant occupy remain building addition lease office building approximately square foot space house commercial clinical development activity lease building expire june respectively gilead option renew fiveyear term addition june gilead option purchase building specify amountswe occupy facility san dimas california location lease approximately square foot space house research development activity manufacture certain administrative function lease expire november renewal option present addition lease adjacent warehouse facility square foot space use product distribution administrative function lease expire november renewal option durham north carolina lease approximately square foot administrative office laboratory space sublease approximately square foot party lease expire october gilead option renew lease sevenyear term addition lease approximately square foot space aggregate sale market regulatory finance information technology human resource operation europe australia include prepaid year lease square foot manufacturing distribution facility ireland lease expiration date believe facility adequate suitable current nearterm future need item legal proceeding complaint follow case allege large number defendant include gilead overcharge governmental entity name plaintiff pharmaceutical product furnish participant medicaid program general complaint assert claim federal state law alabama state action include state law claim seek treble damage attorney fee litigation preliminary stage possible predict outcome date gilead serve process case county westchester v abbott laboratories et al intend defend case vigorously outcome case predict time amount accrue county westchester v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit file gilead approximately defendant august amend include approximately defendant january city new york v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit file gilead approximately defendant august amend approximately defendant january county rockland v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit originally gilead defendant amend include claim gilead approximately defendant january state alabama v abbott laboratories et al pending circuit court montgomery county alabama lawsuit file gilead approximately defendant january purport class action complaint file november united states district court northern district california gilead certain executive officer complaint allege defendant violate federal security law specifically section b securities exchange act rule b securities exchange commission make certain allegedly false misleading statement omission plaintiff seek unspecified damage behalf purport class purchaser gilead security period july october similar action subsequently file court issue order consolidate lawsuit single action december february court issue order appoint lead plaintiff consolidated action april lead plaintiff behalf purport class file consolidated amend complaint june gilead individual defendant file motion dismiss consolidated amend complaint january court grant defendant motion dismiss leave amend december purport shareholder derivative lawsuit file individual shareholder behalf gilead director certain executive officer superior court state california county san mateo allege thing defendant violate california corporations code breach fiduciary duty gilead gilead name nominal defendant plaintiff seek unspecified damage behalf gilead connection allege insider trading period july october defendant allege breach fiduciary duty abuse control waste mismanagement case consolidate single action january similar case file february later consolidate prior case plaintiff file consolidated complaint amend time recently november gilead demur consolidated complaint court grant demurrer december plaintiff file motion leave file consolidated amend complaint january court grant plaintiff motion render complaint operative complaint intend demur complaint trial schedule june party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position item submission matter vote security holder matter submit vote security holder quarter end december ii item market registrant common equity relate stockholder matter common stock trade nasdaq stock market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq stock market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter september implement twoforone stock split form stock dividend share share amount period present restate reflect stock split february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception anticipate pay foreseeable future item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue purchase inprocess research development total cost expense income loss operation gain sale oncology asset provision benefit income taxis income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute gilead sciences inc select consolidated financial datum continue december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible debt accumulate deficit total stockholder equity gilead record gain million relate warrant eyetech complete initial public offering record makewhole payment million relate redemption million convertible senior debt gilead complete acquisition net asset triangle aggregate purchase price million approximately million purchase price allocate purchase inprocess research development record income tax benefit million relate reduction valuation allowance certain net defer tax asset sell share osi common stock recognize loss sale marketable security million share partial consideration sale oncology asset complete sale oncology asset relate technology osi pharmaceuticals inc record nonoperate gain million record nonoperate gain million sale percent interest proligo gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle effective quarter gilead adopt secs staff accounting bulletin sab revenue recognition financial statement change account change accounting principle february march september gilead implement twoforone stock split form stock dividend share share amount period present restate reflect stock split cash dividend declare pay common stock item management discussion analysis financial condition result operation executive summary operating result mark year growth total revenue reach billion high end cash cash equivalent marketable security billion drive large operate cash flow million year factor contribute improve financial performance important driver continue growth experience hiv product portfolio comprise viread emtriva truvada maintenance ambisome revenue amidst increase competition give increase international sale favorable foreign currency environment europe viread sale increase year year comprise total product sale august launch truvada coformulation viread emtriva united states begin launch truvada european union follow regulatory approval february time depend treatment regimen prescribe physician expect truvada sale partially replace product sale viread emtriva increase future sale hiv product enter joint venture collaboration agreement bms december develop commercialize fixeddose combination gilead truvada bms sustiva united states understand importance clear view wholesaler channel inventory sign inventory management agreement major wholesaler keep strategy active product acquisition inlicense rounded enter collaboration agreement area hcv operating result impact acquisition asset triangle january complete acquisition expand antiviral pipeline triangle development stage company particular focus potential therapy hiv include aid hbv aggregate purchase price million include cash pay million fair value stock option assume million direct transaction cost million employee relate cost million approximately million consideration pay allocate purchase inprocess research development represent fair value triangle incomplete research development program reach technological feasibility alternative future use acquisition date result transaction relate purchase inprocess research development charge operate loss million acquisition important compound acquire opportunity provide create truvada coformulation viread emtriva single pill dose day note consolidated financial statement information triangle acquisition september gilead complete twoforone stock split effect form stock dividend stockholder record august accordingly share share amount period present restate reflect stock split addition certain prior year amount reclassify conform current year presentation management discussion analysis read conjunction consolidated financial statement note include report forwardlooke statement risk factor follow discussion contain forwardlooke statement involve risk uncertainty risk factor discussion read conjunction consolidated financial statement note include report critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance accounting principle generally accept united states preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account inventory clinical trial accrual tax provision base estimate historical experience marketspecific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognitionwe recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure record estimate reduction revenue expect return expire product distributor fee government rebate program medicaid reimbursement customer incentive cash discount prompt payment estimate distributor fee base contractually determine fix percentage sale estimate government rebate program cash discount base contractual term historical utilization rate expectation future utilization rate program estimate product return include new product base ongoing analysis industry historical return pattern include monitor feedback receive sale force customer use satisfaction review inventory datum available wholesaler inventory management agreement assist monitor channel inventory level purchase thirdparty datum monitor prescription new product review long shelf life product sell similar channel monitor activity clinical trial key competitor assess potential impact future sale return expectation necessary expect return market drug generally low shelf life product range month truvada month ambisome viread united states condition competitive market serve drug circumstance change action increase product return estimate offer additional customer incentive result incremental reduction future revenue time return estimate change new incentive offer contract revenue research development record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection reasonably assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead obligation type arrangement revenue recognize manufacturing obligation fulfil ratably development period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require allowance doubtful account balance percentage total account receivable materially change december december believe allowance doubtful account adequate cover anticipate loss current condition significant deterioration factor especially respect government funding reimbursement practice european market materially change expectation result increase allowance doubtful account inventory write inventory base historical review quantity bad batch experience manufacturing process expectation production inventory level perform quality control review individual raw material batch generally record inventory writeoff base estimate obsolescence risk competition primarily shelf life product long current assumption future production inventory level demand competition change actual market condition favorable project management inventory writedown require negatively impact product gross margin result operation clinical trial accrual record accrual estimate clinical preclinical study cost clinical preclinical study perform party contract research organization cro cost significant component research development expense incur million million million respectively cro cost accrue cost clinical study perform cro straightline basis term service period adjust estimate require base ongoing review level effort actually incur cro initially estimate work perform contract occur ratably period expect milestone event total contract completion date expect completion date estimate base term contract past experience similar contract estimate match actual service perform organization determine patient enrollment level measure activity specify contract result validate accrual quarterly write vendor confirmation detail review activity perform significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro generally significant portion total cost associate start activity trial patient enrollment gilead extensively outsource clinical trial activity usually perform small portion startup activity inhouse result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management budget basis cost typically total contract value actual basis percentage range significantly wider contract expand reduced scope compare original budget startup cost particular trial change significantly startup cost usually occur month contract establish milestone event drive nature remain activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix unit price vary length month single dose phase study year complex phase study average length contract upper end range order provide long term safety efficacy datum support commercial launch viread truvada hepsera emtriva december difference actual estimate activity level particular study significant require material adjustment material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant research development expense future periodstax provision develop income tax provision include defer tax asset liability base significant management judgment evaluate realizibility defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination adjustment fourth quarter determine likely certain defer tax asset realized release related valuation allowance result income tax benefit approximately million million respectively similarly determine able realize defer tax asset valuation allowance increase valuation allowance period determination future effective income tax rate affect factor change tax law rate change interpretation law impact accounting employee stock option begin second half overall change future level earning research development capital spending management discuss development selection critical accounting policy audit committee gilead board director audit committee review disclosure present relate result operation total revenue total revenue billion million million include total revenue product sale royalty revenue contract revenue include revenue earn research development rd manufacturing collaboration product sale product sale consist follow thousand change change viread emtriva truvada total hiv product ambisome total product sale product sale increase compare compare primarily increase volume sale hiv product significant percentage product sale continue denominate foreign currency use forward contract hedge percentage forecast international sale primarily denominate euro reduce eliminate fluctuation sale change foreign currency exchange rate loss revenue hedge reduce increase product sale million million million fluctuation exchange rate product sale mainly viread ambisome benefit overall primarily increase exchange rate euro british pound comparison dollar million compare million compare prior experience significant fluctuation distribution channel inventory level speculative purchase major wholesaler result experience increase quarter quarter sale volatility purchase pattern order help alleviate fluctuation july enter inventory management agreement imas amerisourcebergen drug corporation cardinal health inc mckesson corporation major pharmaceutical wholesaler distribute percent portfolio product sell united states agreement implement limit speculative buying help ensure wholesaler purchase consistent customer demand predictable agreement agree pay wholesalers fee exchange product distribution inventory management service market research information return good processing assistance counterfeit product detection service fee record reduction product sale consolidate statement operation additionally term agreement wholesaler agree exceed specify maximum level inventory hand end december believe major wholesaler inventory onhand gilead product month supply compliance contractually specify level viread emtriva truvada approve sale united states october july august respectively viread emtriva approve sale european union february october respectively sale viread total product sale respectively viread sale million sale increase versus million international sale increase versus viread sale million sale increase versus million international sale increase versus emtrivas introduction july sale increase significantly million million august truvada approve sale united states product sale total million december total hiv product sale million higher compare favorable european currency environment majority relate viread sale believe product sale mix change patient currently take viread andor emtriva switch truvada look hiv product sale collectively relevant basis periodoverperiod comparison sale hiv product percentage total product sale respectively expect sale hiv product billion billion year sale ambisome total product sale respectively hiv hbv product sale continue increase ambisome sale decrease percentage total product sale ambisome sale million sale decrease versus million international sale increase versus ambisome sale million sale decrease versus million international sale increase report ambisome sale million high favorable currency environment compare volume basis ambisome sale united states decrease sale volume europe increase slightly compare analyze decrease sale important note product sale decrease compare volume decrease discussion ambisome sale relate solely sale ambisome fujisawa record manufacturing cost great manufacturing efficiency unit manufacturing cost ambisome decrease decrease revenuesreporte sale fujisawa royalty earn sale ambisome fujisawa discuss continue competition expect ambisome sale range million million royalty revenue record royalty revenue million compare million million threeyear period significant source royalty revenue result sale tamiflu roche sale ambisome united states fujisawa copromotion arrangement royalty revenue earn sale tamiflu million million million respectively royalty revenue earn sale ambisome fujisawa million million million respectively difficult estimate party product sale record royalty revenue roche quarter arrear severe influenza epidemic united states late early royalty revenue increase substantially second quarter increase awareness discussion supply influenza treatment increase roche sale tamiflu consequently royaltie fourth quarter contract revenue total contract revenue million compare million million contract revenue consist primarily million research milestone revenue earn eyetech pharmaceutical include million net milestone payment earn file new drug application eyetech europe united states macugen pegaptanib sodium injection primary source contract revenue consist million license fee earn conjunction licensing agreement eyetech macugen contract revenue primarily consist million licensing selex process patent estate archemix collectibility concern recognize cash basis million milestone payment roche european prophylaxis treatment approval tamiflu december complete sale oncology asset osi term agreement entitle additional payment osi million cash combination cash osi stock osi reach certain development milestone nx advanced oncology product candidate sell osi relate manufacturing agreement produce nx gs l liposomal product include sale manufacturing facility san dimas california recognize million million million respectively contract revenue manufacturing agreement cost good sell product gross margin follow table indicate cost good sell product gross margin thousand change change total product sale cost good sell gross margin percentage gross margin relatively flat positive impact improvement certain manufacturing process favorable foreign currency environment offset change product sale mix compare gross margin improve primarily change product mix viread high margin product contribute significantly net product sale change foreign currency exchange rate impact gross margin price product currency country product sell significant majority manufacturing cost dollar example increase value foreign currency relative dollar positively impact gross margin manufacturing cost remain approximately revenue translate dollar increase weaken dollar positively impact gross revenue gross margin effect foreign currency exchange rate moderate hedging program forecast international sale potential impact unpredictable uncontrollable change exchange rate relative dollar mix product sale hiv product hepsera ambisome expect gross margin consistent range research development expense follow table summarize research development expense major component thousand change change research clinical development pharmaceutical development total major category research development rd expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist support facility relate cost research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis prior clinical development consist clinical trial expense phase phase united states phase european clinical trial include sale general administrative sga order well reflect nature european phase clinical trial begin record clinical trial expense research development order consistent current year presentation million million expense reclassify sell general administrative research development expense year end december respectively million increase rd expense primarily attributable increase salary million largely high headcount increase contract research organization cost million associate increase clinical activity million research license fee pay relation hepatitis c collaboration agreement effective fourth quarter new collaboration enter achillion genelab require pay aggregate license fee million expense rd underlie technology alternative future use increase rd activity partially offset decrease spending discontinuation program gs gs focus thedevelopment certain hiv investigational product important note rd expense include reimbursement gilead million settlement contractual dispute vendor million increase rd spending versus primarily attributable increase salary million largely high headcount increase clinical supply cost million increase clinical trial cost associate development emtriva truvada coformulation viread emtriva mention settle contractual dispute vendor result reimbursement million record research development expense expect rd expense approximately million million estimate increase expense level reflect increase spend internal research development effort cost associate postmarkete study support product exclude expense incur associate potential collaboration strategic acquisition include license milestone fee cost sharing arrangement impact accounting employee stock base compensation begin second half industry report indicate biopharmaceutical company generally take year average year research develop bring market new prescription medicine united states average generally consistent project undertake internally recent product development timeline slightly accelerate basis drug development united states process include step define fda process begin file ind successful allow opportunity clinical study potential new medicine clinical development typically involve phase study phase generally account average seven year drug total development time significant cost associate clinical development phase trial tend long large study conduct drug development process currently product development phase study successful development product highly uncertain completion date rd expense vary significantly product difficult predict successful development fda approval product undertake additional study try expand product label market potential complete discussion risk uncertainty associate complete development product risk factor affect gilead section item sell general administrative expense follow table highlight year year change sell general administrative expense thousand change change sell general administrative sga expense year end december million compare million year end december include reclassification phase iv clinical trial expense incur rd million significant increase expense compare primarily increase salary million largely high headcount increase consulting fee million relate sarbanesoxley compliance business strategy consulting increase cost million relate speaker program grant journal advertising remainder increase sga expense compare increase global marketing effort increase infrastructure require support growth business infrastructure investment implement reorganization sale marketing function newly create commercial division conjunction reorganization create fill new position executive vicepresident commercial operation responsibility global commercial operation strategy product portfolio increase expense compare include reclassification phase iv clinical trial expense rd million primarily increase salary million largely high headcount increase hedging cost million increase cost million relate marketing meeting grant increase general director officer insurance million remainder increase sga expense global sale marketing effort include expansion european sale force increase infrastructure require support growth business expect sga expense approximately million million primarily anticipated launch cost truvada european union ongoing investment global commercial organization hire promotional program exclude expense incur associate potential collaboration strategic acquisition impact apply new standard accounting employee stock base compensation begin second half purchase inprocess research development connection acquisition net asset triangle complete january record purchase inprocess research development expense million quarter charge triangle incomplete research development program reach technological feasibility alternative future use acquisition date value purchase inprocess research development determine estimate related future net cash flow present value risk adjust discount rate discount rate significant assumption base estimate weighted average cost capital adjust upward risk associate project acquire project cash flow acquire project base estimate revenue operate profit relate project consider stage development potential product acquire time resource need complete development approval product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound include obtain fda regulatory approval risk relate viability potential alternative treatment future target market summary program acquisition date update subsequent development february follow estimate acquisition date fair value program description status development millionsemtricitabine hiv nucleoside analogue phase study complete show prior acquisition date inhibitor hiv replication marketing approval receive patient fda july emtriva european union approval receive european commission october emtricitabinetenofovir df fixeddose acquisition date work fix dose combination coformulation tenofovir commence potential co hiv therapy emtricitabine formulation extent work emtricitabine single agent progress march application marketing approval submit united states european union august marketing approval united states receive fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union receive february amdoxovir hiv purine dioxolane program phase trial nucleoside offer acquisition date terminate advantage license agreement emory market nucleosides university university activity georgia research foundation inc drug resistant development discontinue virus exhibit patient hiv infection clevudine hbv pyrimidine nucleoside program phase trial analogue acquisition date august show inhibitor licensing agreement bukwang hbv replication patient pharm ind co ltd terminate chronically infect development discontinue hbv emtricitabine hbv inhibitor hbv phase trial complete replication patient december chronically infect hbv asset impairment record asset impairment charge million certain longlived asset primarily leasehold improvement manufacture laboratory equipment noncash charge drive decision december terminate liposomal research development activity san dimas discontinue daunoxome product line impairment base analysis undiscounte cash flow generate affected asset compare carry value carrying value exceed related estimate undiscounted cash flow write carry value long live asset estimate fair value subsequent decision discontinue daunoxome product line receive unanticipated request europe ask gilead reconsider sell daunoxome result request management decide continue sell product certain country evaluate supply sale strategy respect daunoxome accordance generally accept accounting principle new cost basis impair asset adjust new fact circumstance gain loss marketable security pursuant agreement eyetech enter march receive warrant purchase share eyetech series b convertible prefer stock exercisable price share january eyetech complete initial public offering common stock time adjust fair value warrant result gain million time fair value warrant estimate blackschole valuation model volatility rate discount rate end quarter exercise warrant net basis share eyetech common stock consideration exercise price subsequently hold share eyetech common stock second quarter sell eyetech share own realize gain approximately million include interest income net year end december july sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million year end december makewhole payment debt redemption october gilead call redemption outstanding convertible senior note december november convertible senior note call provisional redemption base market price gilead common stock exceed certain threshold aggregate principal outstanding note million convertible senior note redeemable redemption price equal principal note plus cash payment equal accrue unpaid interest redemption date cash makewhole payment equal principal value note interest actually pay accrue unpaid date issuance note redemption date interest convertible senior note cease accrue redemption date remain right holder receive redemption payment include accrue unpaid interest redemption date makewhole payment alternatively note holder elect convert note share gilead common stock price share share gilead common stock principal note holder substantially ofthe outstanding note convert note share gilead common stock prior november redemption date result conversion share common stock issue note holder connection redemption gilead pay aggregate makewhole payment million note holder interest income net record interest income million compare million million increase compare primarily attributable high cash balance yield past year decrease compare attributable significant decline interest rate low average cash balance acquisition net asset triangle purchase foster city campus partially offset positive cash flow operation interest income depend principally prevail interest rate level cash cash equivalent marketable security balance interest expense incur interest expense million compare million million decrease primarily conversion million convertible subordinated debt share common stock december outstanding debt consist million convertible senior debt issue december november convert convertible senior note significant increase year interest million convertible senior note issue december interest expense consist primarily interest million convertible subordinate note convert share common stock december expect interest expense decrease compare primarily conversion million convertible senior note november provision benefit income taxis provision benefit income taxis million million million respectively effective income tax rate differ federal statutory rate generally state taxis offset recognition previously unbenefitte net operating loss tax credit carryforward certain earning tax foreign tax rate jurisdiction low tax rate taxis provide earning plan permanently reinveste outside united states tax benefit include reversal valuation allowance certain defer tax asset december conclude likely realize portion benefit relate defer tax asset accordingly reduce valuation allowance asset record tax benefit million recognition defer tax asset impact cash flow partially offset tax benefit income tax expense associate income earn foreign subsidiary foreign loss benefit low tax rate nontax deductibility purchase inprocess research development significant net operating loss carryforward reduce tax liability exclude benefit relate reversal valuation allowance write purchase inprocess research development effective tax rate income tax expense primarily associate income earn foreign subsidiary significant net operating loss united states provision reduce change income tax law law allow net operating loss carryforward deduction offset alternative minimum taxable income result reduction income tax record previous year million october american jobs creation act ajca sign law ajca allow deduction certain foreign earning repatriate define ajca elect apply provision qualify earning repatriation fiscal start evaluation effect repatriation provision expect able complete evaluation congress treasury department provide additional clarify language key element provision expect complete evaluation effect repatriation provision reasonable period time follow publication additional clarify language range possible amount consider repatriation provision zero million maximum allowable define ajca currently relate potential range impact income taxis reasonably estimate liquidity capital resource cash cash equivalent marketable security total billion december million december increase million primarily net cash provide operation million proceed issuance stock employee stock plan million partially offset capital expenditure million cash decrease million primarily acquisition triangle net cash impact million purchase foster city campus million capital expenditure million partially offset proceed issuance stock employee stock plan million work capital december billion compare billion december significant change working capital include million decrease current defer tax asset offset million increase account receivable million increase inventory million decrease current defer tax asset primarily utilization net operating loss tax credit carryforward offset taxable income account receivable increase million primarily increase sale viread united states europe sale new product truvada launch united states half million increase inventory primarily increase purchase raw material production viread truvada inventory meet increase sale demand current liability increase million primarily follow million increase medicaid rebate obligation associate high sale viread million increase defer revenue primarily royalty receive roche million increase liability associate fair value forward currency contract dollar continue weaken european currency million increase account payable primarily increase raw material purchase support viread truvada sale growth million increase increase compensation cost employee benefit add headcount increase million distributor fee owe pay inventory management agreement enter july increase current liability partially offset million decrease accrue clinical preclinical expense result decrease activity associate clinical trial program viread hepsera end capital expenditure million compare million million expenditure primarily domestic international facility improvement include approximately million associate completion pilot plant foster city todevelop drug process prepare material supply clinical trial additional spending laboratory manufacturing equipment accommodate growth capital expenditure relate research development million spend million spend million spend expect capital spending million million increase infrastructure need high rd spending believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include commercial performance current future product progress scope research development effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire manufacturing capability additional office facility possibility acquire company new product establishment additional collaborative relationship company defense cost associate settlement adverse result litigation future require additional funding form proceed equity debt financing universal shelf registration statement file december potential issuance million security additional collaborative agreement corporate entity funding require assure available favorable term subsidiary establish variety subsidiary country purpose conduct business location subsidiary consolidate financial statement variable interest entity unconsolidate financial statement involve nonexchange trade commodity contract account fair value commercial commitment relate party employee loan contractual obligation contractual obligation form capital operating lease noncancelable raw material supply arrangement clinical research organization contract follow table summarize contractual obligation december thousands payment period contractual obligation total year year year year capital lease obligation operating lease obligation capital commitment inventory purchase obligation clinical trial total december firm capital project commitment approximately million relate facility improvement addition budget significant capital expenditure mainly anticipate increase infrastructure need high rd spending capital spend future year december firm commitment purchase active pharmaceutical ingredient amount disclose represent minimum purchase requirement actual purchase differ significantly amount december clinical study clinical trial phase significant expenditure contract research organization contract cancelable generally cancel contract amount reflect commitment base exist contract reflect future modification exist contract anticipate potential new contract recent accounting pronouncement december fasb issue sfas revise sharebased payment sfas r revision sfas sfas r supercede apb amends sfas statement cash flow sfas r require sharebase payment employee director include grant stock option recognize statement operation base fair value begin interim annual period june early adoption permit pro forma disclosure previously permit sfas long alternative financial statement recognition expect adopt sfas r quarter fiscal begin july sfas r determine appropriate fair value model value sharebase payment amortization method compensation cost transition method date adoption transition method include prospective retroactive adoption option retroactive option prior period restate begin year adoption period present prospective method require compensation expense record unvested stock option restrict stock begin quarter adoption sfas r retroactive method record compensation expense unvested stock option restrict stock begin period restate currently evaluate requirement sfas r option valuation methodology relate employee director stock option employee stock purchase plan determine method adoption effect adoptingsfas r expect adoption sfas r material impact consolidate result operation earning share impact adoption sfas r predict time depend thing level sharebase payment grant future method adoption option valuation method sfas r require benefit tax deduction excess recognize compensation cost report finance cash flow operate cash flow require current literature requirement reduce net operating cash flow increase net financing cash flow period adoption estimate amount future depend thing employee director exercise stock option operate cash flow recognize prior period relate tax deduction million million million respectively current estimate option value blackschole method indicative result valuation methodology ultimately adopt gilead item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity united states sale activity europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business mitigate impact change currency exchange rate cash flow foreign currency sale transaction enter foreign exchange forward contract hedge foreign currencydenominate net monetary asset liabilitie significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition prior hedge exposure impact fluctuate foreign exchange rate forecast sale january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency recent year weaken dollar foreign currency exchange fluctuation positively impact product sale gross margin impact favorable foreign currency environment moderated hedge contract enter follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward contract december contract maturity year average rate state term foreign currency dollar fair value represent estimate settlement amount december notional amount fair value dollar thousand fair value currency notional average rate december british pound euro australian dollar total notional million fair value million open foreign exchange forward contract december compare total notional million fair value million open foreign exchange forward contract december significant increase outstanding contract primarily attribute project increase revenue forecast periods interest rate risk portfolio availableforsale investment security fixedrate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate fixedrate interestbeare asset fixedrate liability december dollar thousand fair value year end december december total asset availableforsale security average interest rate liability longterm obligation include current portion average interest rate longterm obligation consist capital lease operating lease net noncancelable sublease interest portion payment include international credit riskour account receivable balance december million compare million december million december growth account receivable balance primarily high product sale viread united states europe certain country payment typically slow primarily greece italy portugal spain account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase credit risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total approximately million approximately million day past date experience significant loss respect collection account receivable believe substantially account receivable balance collectible perform credit evaluation customer financial condition generally require collateral item financial statement supplementary datum financial statement require item set forth begin report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness design operation disclosure control procedure define sec rule control procedure company design ensure information require disclose company report file securities exchange act exchange act record process summarize report require time period base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define security exchange act rule af internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include principal executive officer principal financial officer conduct evaluation effectiveness internal control financial reporting criterion set forth committee sponsor organization treadway commission coso internal control integrate framework base evaluation conclude internal control financial reporting effective december ernst young llp independent register public accounting firm audit consolidated financial statement include issue audit report assessment internal control financial reporting c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting item b information iii item director executive officer registrant information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting proxy statement headings nominee executive officer board director audit committee compliance section security exchange act gilead write code ethic apply director employee include executive officer code ethic available gilead website httpwwwinvestorsgileadcom change waiver code ethic disclose website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee report item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction information require item incorporate reference section proxy statement heading compensation committee interlock insider participation certain transaction executive compensationitem principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item exhibit financial statement schedule follow document file index list financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc date november agreement plan merger registrant simbolo acquisition sub inc wholly own subsidiary registrant triangle pharmaceutical inc date december amend restate certificate incorporation registrant amend bylaw registrant amend restate march reference exhibit exhibit amend restate right agreement date october registrant chasemellon shareholder services llc agreement plan merger date february registrant gazelle acquisition sub inc nexstar pharmaceuticals inc registration right agreement date december registrant goldman sach co amendment amend restate right agreement date october registrant mellon investor service llc form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee registrant incentive stock option plan relate agreement registrant supplemental stock option plan relate agreement registrant employee stock purchase plan amend march registrant stock option plan amend restate april amend january amend january form nonqualified stock option issue certain executive officer director letter agreement date september registrant iocbrega exhibit certain confidential information omit amendment agreement date october registrant iocbrega relate license agreement exhibit certain confidential information omit amendment agreement date december registrant iocbrega registrant nonemployee director stock option plan amend january amend january development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september certain confidential information omit nexstar pharmaceutical incs incentive stock plan adopt february amend nexstar pharmaceutical inc director option plan adopt july vestar inc stock option plan lease date february registrant majestic mapa property llc lease date february registrant majestic mapa property llc assignment royalty agreement date december effective june vestar inc city hope national medical center agreement fujisawa usa inc vestar inc date august amendment thereto date amendment agreement fujisawa usa inc vestar inc date april fujisawa usa inc vestar inc certain confidential information omit amendment agreement fujisawa usa inc registrant date march agreement fujisawa usa inc vestar inc date august lease date july registrant majestic realty co majesticmapa property llc amendment thereto date march license distribution agreement date september sumitomo pharmaceutical co ltd nexstar pharmaceuticals inc certain confidential information omit settlement agreement date august nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omit amendment date april sumitomo pharmaceutical co ltd nexstar pharmaceuticals inc license distribution agreement date september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc defer compensation plan licensing agreement date april gilead world market limited glaxo group limited employment agreement date july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch date august license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd date march license agreement triangle pharmaceuticals inc emory university coviracil ftc date april exclusive license agreement triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date settlement agreement triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited date amendment license agreement triangle pharmaceuticals inc emory university date amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date july second amendment license agreement triangle pharmaceuticals inc emory university date july supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories date july settlement exclusive license agreement triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation date august second amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date august manufacture supply agreement gilead world markets ltd ppgsipsy sas enter january gilead sciences inc severance plan adopt effective january amendment license agreement triangle pharmaceuticals inc emory university date lease agreement date june th registrant gra associates limited llc premise locate university drive durham north carolina master clinical commercial supply agreement date january gilead world markets ltd gilead sciences inc patheon inc toll manufacturing agreement date august gilead world markets ltd gilead sciences inc altana pharma oranienburg gmbh licensing agreement date march amend december april gilead sciences inc eyetech pharmaceuticals inc amendment licensing agreement date eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement date december eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement date august eyetech pharmaceuticals inc gilead sciences inc amendment date license agreement date april glaxo group limited gilead world market limited amendment date january licensing agreement date april glaxo group limited gilead world market limited employment agreement date april gilead sciences inc mark l perry gilead sciences inc equity incentive plan amend july collaboration agreement gilead sciences inc gilead holdings llc bristol myers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date december th amendment license agreement triangle pharmaceuticals inc emory university date subsidiary registrant consent independent register public accounting firm power attorney reference signature section certification section certification section certification file exhibit registrant annual report fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc quarterly report form q quarter end june incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file march incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc form q quarterly period end september incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file march exhibit nexstar pharmaceutical inc registration statement form file incorporate reference file exhibit nexstar pharmaceutical inc form q quarterly period end september incorporate reference file exhibit nexstar pharmaceutical inc form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form k file january incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit triangle pharmaceutical inc registration statement form amend incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc current report form k file september incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate referencefile exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant fiscal year end december incorporate reference certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule b securities exchange act gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list item annual report financial statement schedule responsibility management gilead sciences inc responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states effectiveness gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date march express unqualified opinion thereon ernst young llp palo alto california march report independent register public accounting firm board director stockholder gilead sciences inc audit management assessment include accompany management annual report internal control financial reporting include item gilead sciences inc maintain effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internalcontrol financial reporting responsibility express opinion management assessment opinion effectiveness gilead sciences inc internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion management assessment gilead sciences inc maintain effective internal control financial reporting december fairly state material respect base coso criterion opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december relate financial statement schedule report date march express unqualified opinion thereon ernst young llp palo alto california march gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent marketable security account receivable net allowance december december inventory defer tax asset prepay expense total current asset property plant equipment net noncurrent defer tax asset noncurrent asset liability stockholder equity current liability account payable accrue clinical preclinical expense accrue compensation employee benefit accrue liability defer revenue longterm obligation year total current liability longterm defer revenue longterm obligation year convertible senior debt commitment contingency stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income loss defer stock compensation accumulate deficit total stockholder equity accompany note gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative purchase inprocess research development asset impairment total cost expense income loss operation gain loss marketable security makewhole payment convertible debt redemption interest income net interest expense income loss provision benefit income taxis provision benefit income taxis net income loss net income loss sharebasic share share calculationbasic net income loss sharedilute share share calculationdilute accompany note gilead sciences inc consolidated statement stockholder equity thousand accumulate additional comprehensive total common stock paidin income defer stock accumulate stockholder share capital loss compensation deficit equity balance december net income unrealize loss availableforsale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan compensatory stock transaction balance december net loss unrealize loss availableforsale security net foreign currency translation adjustment unrealize loss cash flow hedge net comprehensive loss conversion convertible subordinate debt acquisition triangle pharmaceuticals inc issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock compensation compensatory stock transaction balance december net income unrealize loss availableforsale security net foreign currency translation adjustment unrealize loss cash flow hedge net comprehensive income conversion convertible senior debt net debt issuance cost issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock compensation compensatory stock transaction balance december accompany note gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization purchase inprocess research development asset impairment loss disposal property plant equipment loss gain marketable security defer tax asset tax benefit employee stock plan noncash transaction change operate asset liability account receivable net inventory prepaid expense asset account payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale maturity marketable security acquisition triangle net asset net cash acquire acquisition real estate capital expenditure issuance note triangle net cash provide investing activity financing activity proceed issuance common stock repayment longterm debt proceed issuance convertible senior note net issuance cost net cash provide financing activity effect exchange rate change cash net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity common stock issue conversion debt reclassification defer debt issuance cost additional paidin capital conversion debt accompany note gilead sciences inc note consolidated financial statement december organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease multinational company revenue approve product marketing operation country focus research clinical program antiinfective currently market viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection vistide cidofovir injection treatment cmv retinitis roche market tamiflu oseltamivir phosphate treatment influenza royalty pay collaborative agreement january eyetech start market macugen pegaptanib sodium injection united states treatment neovascular agerelate macular degeneration milestone royalty pay collaborative agreement accompany consolidated financial statement include account gilead whollyowne subsidiary significant intercompany transaction eliminate certain prior year amount reclassify consistent current year presentation research development expense stock split march september gilead complete twoforone stock split effect form stock dividend stockholder record february august respectively accordingly share share amount period present reflect stock split critical accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoing basis management evaluate estimate include related revenue recognition allowance doubtful account inventory clinical trial accrual tax provision base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure provide customer general right product return accept return products united states expire year expiration product gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue deem damage defective receive customer recognition revenue product sale provision estimate future return product expire government reimbursement certain distributor fee customer incentive cash discount prompt payment estimate government reimbursement cash discount base contractual term expectation utilization rate program estimate distributor fee base contractual term estimate product return include new product base ongoing analysis industry historical return pattern party datum assist monitor channel inventory level subsequent prescription contract revenue research development record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection reasonably assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead obligation type arrangement revenue recognize manufacturing obligation fulfil ratably development period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue royalty revenue sale ambisome recognize month follow correspond sale occur royalty revenue sale hepsera tamiflu vistide recognize receive quarter follow quarter correspond sale occur shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expensesmajor component research development rd expense consist personnel cost include salary benefit clinical study perform contract research organization cro material supply overhead allocation consist administrative facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial pharmaceutical development cost consist product formulation chemical analysis gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue charge research development cost include clinical preclinical study cost expense incur consistent statement financial accounting standard sfas accounting research development cost cost significant component rd expense clinical preclinical study perform party cro accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro initially estimate work perform contract occur ratably service period expect milestone event total contract completion date expect completion date estimate base term contract past experience similar contract monitor level performance contract include extent patient enrollment activity communication cro adjust estimate require quarterly basis expense reflect actual effort expend cro material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate contract include additional termination payment payable gilead terminate contract additional termination payment record contract terminate order well reflect nature european phase clinical trial gilead begin recording cost rd expense amount previously classify sell general administrative expense consolidate statement operation order consistent current period presentation million million expense reclassify sell general administrative research development expense year end december respectively advertising expense expense cost advertising include promotional expense incur advertising expense million million million stockbase compensation accordance provision sfas accounting stockbase compensation amend sfas accounting stockbase compensationtransition disclosure sfas elect continue follow accounting principle board opinion apb accounting stock issue employee interpretation fin account certain transaction involve stock compensationan interpretation apb opinion accounting employee stock option plan apb exercise price gilead employee director stock option equal exceed fair value underlie stock date grant compensation expense recognize elect follow intrinsic value method prescribe apb evaluate approach accounting stock option light recent industry regulatory development gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue table present net income loss basic diluted net income loss share compensation cost gilead nexstar pharmaceuticals inc nexstar triangle stock option plan employee stock purchase plan espp determine base estimate fair value award plan grant purchase date accordance sfa thousand share amount year end december net income lossa report add stockbased employee compensation expense include report net income loss net relate tax effect deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma net income loss net income loss share basica report basicpro forma diluteda report dilutedpro forma fair value award grant stock option plan espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility employee stock option characteristic significantly different trade option model develop future generate fair value differ calculate base blackschole calculate estimate fair value award multiple option approach follow assumption year end december expect life year vest date stock option espp discount rate stock option espp volatility expect dividend yield gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue fourth quarter refine volatility assumption arrive fair value stock award purpose calculate expect volatility rate begin time period well reflect current stage development length time public company drug approval past year enable achieve positive cash flow operation believe estimate volatility rate well reflect expect volatility common stock future recent threeyear time period purpose calculate expect volatility twoyear time period derive weight average volatility fourth quarter weight average volatility quarter weight average estimate fair value espp share purchase earning loss share basic earning loss share calculate base weightedaverage number common share outstanding year dilute earning loss share calculate base weightedaverage number common share dilutive security dilutive potential common share result assume exercise outstanding stock option equivalent determine base treasury stock method dilutive potential common share result assumed conversion convertible note determine base ifconverted method follow table reconciliation numerator denominator calculation basic diluted earning loss share thousands year end december numerator net income loss calculation basic earning loss share interest expense makewhole payment convertible debt redemption net income loss calculation dilute earning loss share denominator weightedaverage common share outstanding calculation basic earning loss share effect dilutive security stock option equivalent convertible debt weightedaverage common share outstanding calculation dilute earning loss share gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue diluted net loss share exclude prorate effect million convertible subordinated note convert approximately million share effect million convertible senior note convert approximately million share outstanding stock option equivalent million share effect antidilutive diluted net income share exclude effect million convertible subordinated note convert approximately million share million convertible senior note convert approximately million share effect assume conversion antidilutive cash cash equivalent consider highly liquid investment insignificant interest rate risk remain maturity month purchase date cash equivalent enter overnight repurchase agreement purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repurchase agreement repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell gilead eligible instrument investment policy include cash equivalent include commercial paper money market fund bank obligation marketable nonmarketable security determine appropriate classification marketable security consist solely debt security time purchase reevaluate designation balance sheet date marketable security classify availableforsale carry estimate fair value report cash equivalent marketable security december cash cash equivalent include million security designate availableforsale million december unrealize gain loss availableforsale security exclude earning report separate component stockholder equity interest income net include interest dividend amortization purchase premium discount realize gain loss sale security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value determine decline fair value investment accounting basis otherthantemporary reduce carry value security hold record loss decline reduction require past year result enter collaboration time time gilead hold stock nonpublic company record nonmarketable security cost noncurrent asset amount otherthantemporary impairment regularly review investment indicator impairment investment nonmarketable security material period present recognize otherthantemporary decline past year gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue concentration risk subject credit risk portfolio cash equivalent marketable security policy limit amount invest security duration industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale significant trade account receivable arise product sale viread united states europe certain country payment typically slow primarily greece italy portugal spain account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total approximately million approximately million day past base contractual term receivable december past receivables country million approximately million day past date experience significant loss respect collection account receivable believe past account receivable net allowance reflect consolidated balance sheet collectible perform credit evaluation customer financial condition generally require collateral material utilize operation facility example depend single supplier high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol manufacture ambisome currently contract manufacturer qualified manufacture truvada tablet supply supplier interrupt reason unable ship viread ambisome hepsera emtriva vistide truvada supply product development clinical trial account receivable trade account receivable record net allowance cash discount prompt payment doubtful account government chargeback sale return estimate cash discount government chargeback sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual obligation historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice historically level uncollectible account receivable write insignificant consistent management expectation gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continuedinventorie inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize historically inventory writedown insignificant consistent management expectation property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method land depreciate estimate useful life follow year description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement life relate lease office computer equipment include capitalize computer software capitalize software purchase internally develop computer software leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction progress include property plant equipment interest capitalize insignificant intangible asset intangible asset definite life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable inplace lease intangible asset amortize remain period relate lease term discuss note impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue significant adverse change legal factor business climate affect value asset adverse action assessment food drug administration regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset eventual disposition carry asset estimate future cash flow asset liability group low level identifiable cash flow largely independent cash flow generate group undiscounte future cash flow carry asset impairment loss measure excess carrying value asset estimate fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income loss accumulate separate component stockholder equity net foreign exchange transaction gain loss report sell general administrative expense consolidate statement operation realize loss million million realize gain million hedge certain foreign currency exposure related outstanding trade account receivable forecast product sale foreign exchange forward contract general market risk contract offset correspond gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time gilead limit risk counterpartie contract unable perform transact major bank limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract ie contract positive fair value date default enter speculative foreign currency transaction write option presently hedge net investment foreign subsidiary accounting hedge net monetary asset liability record change fair value sell general administrative expense derivative instrument designate hedge sfas nos accounting derivative instrument hedge activity collectively refer sfas gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue selectively hedge anticipate currency exposure purchase forward contract hedge anticipate product sale year designate cash flow hedge sfas unrealized gain loss underlie forward contract record comprehensive income recognize earning forecast transaction occur december december net unrealized loss open foreign exchange forward contract million million respectively loss revenue hedge reduce product sale million million million notional amount forward exchange contract outstanding million december million december contract maturity year note discussion derivative financial instrument fair value financial instrument financial instrument consist principally cash cash equivalent marketable security account receivable certain noncurrent asset forward foreign exchange contract account payable longterm obligation cash cash equivalent marketable security forward foreign exchange contract hedge account receivable report respective fair value balance sheet forward foreign exchange contract hedge firmly commit purchase forecast sale record fair value net relate deferred gain loss result report net balance zero gilead call convertible senior note redemption october convert million share gilead common stock november december fair value convertible senior note million carry value million gilead call convertible subordinate note redemption november convert million share gilead common stock december fair value convertible senior note december determine obtain quote market maker note believe remain financial instrument report consolidated balance sheet amount approximate current fair value recent accounting pronouncement december fasb issue sfas revise sharebased payment sfas r revision sfas sfas r supercede apb amends sfas statement cash flow sfas r require sharebase payment employee director include grant stock option recognize statement operation base fair value begin interim annual period june early adoption permit pro forma disclosure previously permit sfas long alternative financial statement recognition expect adopt sfas r quarter fiscal begin july sfas r determine appropriate fair value model value sharebase payment amortization method compensation cost transition method date adoption transition method include prospective retroactive adoption option retroactive option prior period restate begin year adoption period present prospective method require compensation expense record unvested stock option restrict stock begin quarter gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue adoption sfas r retroactive method record compensation expense unvested stock option restrict stock begin period restate currently evaluate requirement sfas r option valuation methodology relate employee director stock option employee stock purchase plan determine method adoption effect adopt sfas r expect adoption sfas r material impact consolidate result operation earning share impact adoption sfas r predict time depend thing level sharebase payment grant future method adoption option valuation method sfas r require benefit tax deduction excess recognize compensation cost report finance cash flow operate cash flow require current literature requirement reduce net operating cash flow increase net financing cash flow period adoption estimate amount future depend thing employee director exercise stock option operate cash flow recognize prior period relate tax deduction million million million respectively current estimate option value blackschole method indicative result valuation methodology ultimately adopt gilead derivative financial instrument derivative recognize asset liability measure fair value enter foreign currency forward contract hedge change fair value significant monetary asset liability denominate nonfunctional currency derivative designate meet definition fair value hedge change fair value derivative hedge item recognize earning enter foreign currency forward contract generally maturitie month hedge future cash flow relate forecasted product sale foreign denominate currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify hedge relate forecasted foreign currency product sale designate document inception respective hedge designate cash flow hedge evaluate effectiveness monthly term forward contract underlie transaction match inception forward contract effectiveness calculate compare fair value contract estimate change fair value underlie hedged item effective component hedge record accumulate comprehensive income note substantially value report accumulate comprehensive loss december reclassify earning month residual change fair value instrument include result cancellation dedesignation hedge contract ineffectiveness recognize immediately sell general administrative expense impact ineffectiveness significant consolidated statement operation loss million million million hedging contract recognize consolidated statement ofoperation respectively gilead sciences inc note consolidated financial statement continue december derivative financial instrument continue result enter collaboration arrangement gilead hold warrant purchase stock nonpublic company complete initial public offering january note warrant exercise february warrant net exercise feature pursuant sfas classify derivative instrument noncurrent asset december acquisition triangle pharmaceuticals inc january complete acquisition net asset triangle expand antiviral pipeline triangle development stage company particular focus potential therapy hiv include aids hepatitis b virus hbv triangle portfolio consist drug candidate clinical trial include emtriva emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july food drug administration fda grant marketing approval emtriva treatment hiv october european commission grant marketing authorisation emtriva member states european union triangle acquisition account acquisition asset business combination accordance criterion outline emerge issue task force triangle development stage company commence plan principal operation lack necessary element business complete product ability access customer result operation triangle january include consolidated financial statement primarily consist research development expense less extent sell general administrative expense december arrangement contemplate propose acquisition triangle gilead million loan extend triangle work capital corporate purpose triangle issue gilead unsecured convertible promissory note completion acquisition january loan eliminate consolidated financial statement aggregate purchase price million include cash pay million outstanding stock fair value stock option assume million direct transaction cost million employee relate cost million purchase establish workforce reduction plan assume obligation change control agreement acquisition date approximately million employee termination cost change control obligation record liability pay period approximately year december approximately remain liability gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue follow table summarize purchase price allocation january thousand net tangible asset assemble workforce defer compensation inprocess research development million net tangible asset include assume liability million million value assign assemble workforce amortize year estimate useful life asset defer compensation represent intrinsic value unvested stock option assume transaction amortize remain vest period option extend january reversal defer tax asset valuation allowance fourth quarter remain million assemble workforce asset eliminate note gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue approximately million purchase price allocate purchase inprocess research development represent fair value triangle incomplete research development program reach technological feasibility alternative future use acquisition date summary program acquisition date update subsequent development follow estimate acquisition date fair value program description status development millions emtricitab ine f nucleoside analogue phase study complete prior hiv show acquisition date marketing approval inhibitor hiv replication receive fda july patient emtriva european union approval receive european commission october emtricitabine fixeddose coformulation acquisition date work tenofovir df tenofovir emtricitabine commence potential coformulation fix dose extent work combination emtricitabine single agent hiv progress march application therapy marketing approval submit united states european union august marketing approval united states receive fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union receive february amdoxovir purine dioxolane program phase trial hiv nucleoside offer acquisition date terminate advantage license agreement emory university market nucleoside university georgia research activity foundation inc development drug resistant discontinue virus exhibit patient hiv infection clevudine pyrimidine nucleoside program phase trial hbv analogue acquisition date august licensing show inhibitor agreement bukwang pharm ind co hbv replication patient ltd terminate development chronically infect hbv discontinue emtricitabine inhibitor hbv phase trial complete hbv replication patient december chronically infect hbv gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue value acquire inprocess research development determine estimate related future net cash flow present value risk adjust discount rate discount rate significant assumption base estimate weighted average cost capital adjust upward risk associate project acquire project cash flow acquire project base estimate revenue operate profit relate project consider stage development potential product acquire time resource need complete development approval product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound include obtain fda regulatory approval risk relate viability potential alternative treatment future target market acquisition real estate september complete purchase foster city california campus approximately million cash purchase include building total square foot office laboratory space accordance sfas business combination sfas goodwill intangible asset purchase price allocate land building exist inplace lease base estimate relative fair value land building record million million respectively fair value building depreciate remain economic life estimate year market approach value exist lease acquire record intangible asset approximately million amortize straightline basis net rental income approximately year remain term lease accumulate amortization intangible asset million million december december respectively net rental income generate lease amortization intangible asset include interest income net approximately million year end december million year end december future net rental income receive exist lease million million prior amortization inplace lease asset asset impairment fourth quarter record asset impairment charge million certain longlived asset primarily leasehold improvement manufacture laboratory equipment classify hold use noncash charge drive decision terminate liposomal research development activity san dimas discontinue daunoxome daunorubicin citrate liposome injection product line impairment base analysis undiscounte cash flow generate affected asset compare carry value carrying value exceed related estimate undiscounted cash flow write carry value longlive asset estimate fair value accordance sfas accounting impairment disposal longlive asset sfas estimate fair value derive expected cash flow approach gilead sciences inc note consolidated financial statement continue december asset impairment continue subsequent decision discontinue daunoxome product line receive unanticipated request europe ask gilead reconsider sell daunoxome result request management decide continue sell product certain country evaluate supply sale strategy respect daunoxome accordance sfas write asset continue daunoxome product line establish new cost basis asset adjust new fact circumstance gain loss marketable security eyetech pharmaceutical march enter agreement eyetech pharmaceuticals inc eyetech relate proprietary aptamer eye currently know macugen pegaptanib sodium injection pursuant agreement receive warrant purchase share eyetech series b convertible prefer stock exercisable price share january eyetech complete initial public offering common stock time adjust carry value warrant estimate fair value result gain million include consolidated statement operation year end december gain loss marketable security fair value warrant estimate blackschole valuation model volatility rate discount rate end quarter exercise warrant net basis share eyetech common stock consideration exercise price subsequently hold share eyetech common stock second quarter sell eyetech share hold realize gain approximately million include interest income net consolidated statement operation year end december osi pharmaceutical july gilead sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million reflect consolidated statement operation year end december gain loss marketable security gilead sciences inc note consolidated financial statement continue december availableforsale security follow summary availableforsale security record cash equivalent marketable security consolidate balance sheet estimate fair value availableforsale security base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december treasury security obligation government agency corporate debt security assetbacke security debt security total december treasury security obligation government agency corporate debt security assetbacke security debt security total debt security consist primarily money market fund december december security net unrealize gain loss ofapproximately million million respectively follow table present certain information relate sale availableforsale security thousand year end december proceed sale gross realize gain sale gross realize loss sale december million portfolio marketable security exclude million assetbacked security contractual maturity year million portfolio contractual maturity great year year estimate maturity assetbacked security exceed year december marketable security continuous unrealized loss position year gilead sciences inc note consolidated financial statement continue december balance sheet detail thousand december inventory raw material work process finish good total property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction inprogress accumulate depreciation amortization subtotal land total accrue compensation employee benefit accrue bonus accrue compensation employee benefit total accrue liability accrue medicaid rebate fair value forward foreign currency contract value add taxis payable income taxis payable accrue royalty expense liability total joint venture bristolmyer squibb december enter collaboration bristolmyer squibb company bm develop commercialize fixeddose combination gilead truvada bmss sustiva efavirenz united states structure joint venture gilead bms form limited liability company bristol myers squibb gilead sciences llc term collaboration gilead bms grant royaltyfree sublicense joint venture use respective companyowne technology return grant license joint venture use intellectual property result collaboration ownership interest joint venture gilead bms gilead sciences inc note consolidated financial statement continue december joint venture bristolmyer squibb continuedreflect respective economic interest base fraction estimate net selling price fixeddose combination product attributable truvada sustiva respectively adjust annual basis net selling price truvada change time relative net selling price sustiva gilead bmss respective economic interest joint venture vary annually gilead primary responsibility clinical development activity regulatory filing relate new product result collaboration bms gilead share marketing sale effort party provide equivalent sale force effort minimum number year daily operation joint venture govern primary joint committee gilead responsible accounting financial reporting product distribution joint venture party agree provide respective bulk active pharmaceutical ingredient joint venture approximate market value joint venture total equity investment risk expect sufficient allow finance operational activity ongoing funding gilead bms joint venture attribute believe result represent variable interest entity set forth fasb interpretation consolidation variable interest entity fin r expect consolidate result operation financial position joint venture conclude primary beneficiary party absorb majority joint venture expect loss primary beneficiary legal structure joint venture limit recourse creditor general credit asset gilead financial information consolidate operation joint venture begin december capital contribution gilead bms beginning expect consolidate joint venture record minority interest own bms significant intercompany transaction eliminate collaborative arrangement contract achillion pharmaceutical november enter exclusive license collaboration agreement achillion pharmaceuticals inc achillion agreement grant worldwide right research development commercialization certain small molecule hcv replication inhibitor involve hcv protease treatment infection hepatitis c virus hcv collaboration achillion obligate continue development compound accord mutually agree development plan completion proofofconcept clinical study hcvinfecte patient cost incur achieve proofof concept share equally gilead achillion follow proofofconcept study gilead obligated assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration gilead pay million upfront license fee record research development expense gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue future alternative use license technology million investment purchase million share achillion convertible prefer stock record noncurrent asset additionally agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration genelab technology september enter license research collaboration agreement genelabs technologies inc genelabs research develop commercialize certain genelab novel nucleoside inhibitor hcv polymerase treatment chronic infection cause hcv conjunction sign collaboration agreement pay million upfront license fee record research development expense future alternative use technology initially agree term year genelabs obligate lead research effort gilead option extend research term collaboration additional year gilead lead development commercialization activity agree provide annual funding time equivalent fte expect record research development expense obligate additional payment achievement certain milestone pay royalty future net sale select compound develop approve relation collaboration chiron corporation august enter nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutic select hcv drug target agreement gilead receive nonexclusive right use chiron hcv technology develop commercialize product treatment hcv term agreement pay chiron upfront license fee million record research development expense future alternative use license technology agree additional payment chiron certain clinical regulatory contractually determined milestone meet million payment chiron record research development expense additionally obligate royalty payment event product develop licensed technology japan tobacco inc july gilead enter licensing agreement japan tobacco inc japan tobacco japan tobacco commercialize product hiv product portfolio japan agreement include viread emtriva truvada term agreement receive upfront license fee million entitle receive additional cash payment achievement certain milestone japan tobacco pay royalty net sale product japan upfront fee record defer revenue amortize contract revenue period supply product japan tobacco approximately year december receive million milestone payment japan tobacco relate japanese regulatory approval marketing authorization viread amortize gilead sciences inc note consolidated financial statement continueddecember collaborative arrangement contract continue remain period upfront license fee january japan tobacco submit marketing authorization application emtriva truvada japanese regulatory authority emory university april triangle obtain january acquire acquisition triangle exclusive worldwide license emory universitys emory right purify form emtricitabine use hiv hepatitis b field obligate certain milestone royalty payment emory include annual minimum royalty begin year fda registration grant antihiv product incorporate emtricitabine technology united states year registration grant antihepatitis b product incorporate emtricitabine technology certain major market country triangle begin pay license maintenance fee development milestone achieve launch emtriva begin pay royalty emory respect emtricitabine hiv indication pay royalty million million respectively net sale emtriva net sale truvada incorporate emtricitabine technology launch license agreement emory terminate late patent expiration expiration obligation pay royalty addition right terminate agreement entirety respect indication hiv hbv country prior expiration time day notice glaxosmithkline april gilead gsk enter licensing agreement provide gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territory agreement retain right hepsera united states canada eastern western europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china japan korea taiwan addition gsk pay upfront licensing fee million pay million achievement gsk certain regulatory development commercial milestone million million receive approval hepsera million receive canadian approval hepsera aggregate million receive commercial approval hepsera japan south korea taiwan gsk responsibility development commercialization hepsera territory upfront license fee approval milestone record defer revenue total million million million recognize contract revenue respectively million balance defer revenue december amortize contract revenue period supply hepsera gsk agreement approximately year addition gsk require pay gilead royalty net product sale gsk generate sale hepsera epivirhbvzeffix gsk hepatitis product gsk territory gilead begin receive royalty gsk sale hepsera quarter record million royalty revenue recognize royalty revenue gsk quarter follow quarter relate hepsera sale occur gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue osi pharmaceutical december complete sale oncology asset osi pharmaceutical osi term agreement entitle additional payment osi million cash combination cash osi stock osi reach certain development milestone nx advanced oncology product candidate sell osi relate manufacturing agreement produce nx gs l liposomal product include sale manufacturing facility san dimas california recognize million million million respectively contract revenue manufacturing agreement archemix october enter agreement archemix corporation relate selex technology agreement give archemix exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million million require license agreement license equity holdings inc ulehi pay receipts ulehi recognize million million contract revenue respectively receive warrant purchase share archemix common stock value material require license agreement ulehi transfer warrant receipt transfer remainder warrant ulehi additional payment archemix agreement eyetech march enter agreement eyetech pharmaceuticals inc relate macugen macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen responsible research development cost receive million upfront license fee eyetech april recognize revenue ratably oneyear period provide clinical supply product eyetech entitle additional cash payment eyetech million eyetech reach certain macugen milestone royaltie worldwide net sale macugen december enter agreement eyetech supply macugen eyetech year record contract revenue million million respectively connection clinical supply provide eyetech milestone achieve eyetech recognize contact revenue million milestone payment eyetech second quarter file new drug application europe macugen january eyetech receive fda approval sale macugen united states agreement eyetech expire later year commercial sale product develop date patent expire agreement gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue additionally receive warrant purchase share eyetech series b convertible prefer stock exercisable price share price stock issue investor note discussion warrant fujisawa right market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa term fujisawa agreement amend fujisawa gilead copromote ambisome united states fujisawa sole marketing right ambisome canada exclusive marketing right ambisome rest world provide pay royalty fujisawa connection sale significant asian market include china india japan korea taiwan connection sales fujisawa purchase ambisome gilead manufacturing cost sale canada fujisawa purchase ambisome manufacturing cost plus specify percentage fujisawa collect payment sale ambisome united states canada receive fujisawa gross profit sale ambisome united states gross profit include deduction cost good sell give current effective royalty rate approximately fujisawa net sale ambisome united states connection agreement record royalty revenue million million million sumitomo september gilead sumitomo enter agreement pursuant sumitomo agree develop market ambisome japan term agreement sumitomo pay initial million licensing fee withholding taxis million october million milestone payment withholding taxis million march sumitomo require additional payment certain clinical commercial milestone meet pay royalty japanese ambisome sale agreement gilead obligate provide certain quantity ambisome sumitomo charge recognize payment receive revenue supply period ambisome approve marketing japan roche september gilead enter collaboration agreement hoffmannla roche roche develop commercialize therapy treat prevent viral influenza agreement roche receive exclusive worldwide right gilead proprietary influenza neuraminidase inhibitor recognize contract revenue million milestone payment european approval tamiflu treatment prophylaxis recognize contract revenue million milestone payment japanese approval tamiflu prophylaxis milestone receivable agreement addition roche require pay gilead royalty net product sale tamiflu subject reduction certain define manufacturing cost record total million million million tamiflu royalty respectively recognize royalty revenue roche quarter follow quarter relate tamiflu sale occur gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue iocbrega gilead enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement gilead receive exclusive right manufacture use sell nucleotide compound gilead obligate pay iocbrega percentage net revenue receive sale product contain compound subject minimum royalty payment product cover agreement include vistide hepsera viread exclude tamiflu august agreement iocbrega amend include truvada future fixeddose combination product contain license technology gilead currently make quarterly payment iocbrega base percentage vistide hepsera viread truvada net sale pay royalty million million million iocbrega respectively december agreement iocbrega amend provide reduce royalty rate future sale hepsera viread return payment gilead million signing agreement payment record longterm prepay royalty classified noncurrent asset balance sheet december prepay royalty recognize royalty expense expect commercial life viread hepsera amortization million payment begin product launch date viread hepsera longterm obligation longterm obligation consist follow thousand december capital lease obligation monthly installment interest rate range total longterm obligation current portion longterm obligation year future minimum lease payment capital lease obligation follow thousand year end december represent interest total gilead sciences inc note consolidated financial statement continue december longterm obligation continue term agreement require comply certain financial operating covenant december compliance covenant convertible note december gilead issue million convertible senior note december note convertible total share gilead common stock share convertible senior note provisionally redeemable option gilead time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note gilead call convertible senior note redemption october issue share gilead common stock note holder conversion november redemption price equal principal note redeem plus accrue unpaid interest redemption date connection redemption gilead pay makewhole payment million note holder represent equivalent principal value note interest actually pay accrue unpaid date issuance note redemption date conversion million unamortized balance relate debt issuance cost reclassify additional paidin capital december gilead issue million convertible subordinated note december convertible subordinate note convertible total share gilead common stock share convertible subordinate note redeemable option gilead time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance convertible subordinate note record noncurrent asset amortize interest expense straightline basis contractual term convertible subordinate note november gilead call convertible subordinate note redemption convert note share common stock december conversion million unamortized balance relate debt issuance cost reclassify additional paidin capital commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility facility lease foster city california san dimas california durham north carolina expire date foster city lease fiveyear renewal option addition gilead option purchase foster city property specify durham lease seven year renewal option operate lease sale marketing administrative facility europe australia term equipment lease include corporate airplane initial term year annual renewal option year gilead sciences inc note consolidated financial statement continue december commitment contingency continue lease expense operating lease total approximately million million million aggregate noncancelable future minimum rental payment operating lease follow thousand year end december operating lease legal proceeding complaint follow case allege large number defendant include gilead overcharge governmental entity name plaintiff pharmaceutical product furnish participant medicaid program general complaint assert claim federal state law forthe alabama state action include state law claim seek treble damage attorney fee litigation preliminary stage possible predict outcome date gilead serve process case county westchester v abbott laboratories et al intend defend case vigorously outcome case predict time amount accrue county westchester v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit file gilead approximately defendant august amend include approximately defendant january city new york v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit file gilead approximately defendant august amend approximately defendant january county rockland v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit originally gilead defendant amend include claim gilead approximately defendant january state alabama v abbott laboratories et al pending circuit court montgomery county alabama lawsuit file gilead approximately defendant january gilead sciences inc note consolidated financial statement continue december commitment contingency continue purport class action complaint file november united states district court northern district california gilead certain executive officer complaint allege defendant violate federal security law specifically section b securities exchange act rule b securities exchange commission make certain allege false misleading statement plaintiff seek unspecified damage behalf purport class purchaser gilead security period july october similar action subsequently file court issue order consolidate lawsuit single action december february court issue order appoint lead plaintiff consolidated action april lead plaintiff behalf purport class file consolidated amend complaint june gilead individual defendant file motion dismiss consolidated amend complaint january court grant defendant motion dismiss leave amend amount accrue date december purport shareholder derivative lawsuit file individual shareholder behalf gilead director certain executive officer superior court state california county san mateo allege thing defendant violate california corporations code breach fiduciary duty owe gilead gilead name nominal defendant plaintiff seek unspecified damage behalf gilead connection allege insider trading period july october defendant allege breach fiduciary duty abuse control waste mismanagement case consolidate single action january similar case file february later consolidate prior case plaintiff file consolidated complaint amend time recently november gilead demur consolidated complaint court grant demurrer december plaintiff file motion leave file consolidated amend complaint january court grant plaintiff motion render complaint operative complaint intend demur complaint trial schedule june outcome case predict time amount accrue party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position commitment contingency normal course business subject contingency arise matter product liability claim legal proceeding shareholder suit tax matter accrue contingency accordance sfas accounting contingency normal course business enter firm minimum purchase commitment inventoryrelate material certain active pharmaceutical ingredient supplier december approximately million purchase commitment follow million million million million gilead sciences inc note consolidated financial statement continue december stockholder equity prefer stock gilead share authorize preferred stock issuable series board directors board authorize determine designation power preference right series reserve share prefer stock potential issuance preferred share purchase right plan prefer stock outstanding december employee stock purchase plan gilead employee stock purchase plan espp employee purchase share gilead common stock base percentage compensationthe purchase price share equal low market value date offer date purchase total million share common stock reserve issuance espp december million share total share reserve issue espp million share december stock option plan gileads stockholder approve gilead adopt equity incentive plan plan replacement stock option plan plan nonemployee director stock option plan director plan adoption plan include increase number share available issuance remain share available issuance plan director plan plan provide issuance type equity awards incentive stock option nonstatutory stock option stock appreciation right sar dividend equivalent right restrict stock performance unit performance share phantom share plan exercise purchase price incentive stock option shall fair value gilead common stock date grant case nonstatutory stock option sar share exercise price shall fair value gilead common stock date grant case type award exercise purchase price determine plan administrator incentive stock option typically vest year pursuant formula determine board expire year term award shall term state award agreement year date grant eligible participant include employee director consultant gilead employee eligible incentive stock option compensation committee delegate determine award grant vest term december share remain available future grant plan november gilead adopt plan issuance common stock employee consultant option issue plan discretion board incentive stock option nonqualifie stock option plan amend exercise price stock option equal fair value gilead common stock date grant option vest year pursuant formula determine board expire year plan amend restate april extend term plan stockholder approve amendment plan increase gilead sciences inc note consolidated financial statement continue december stockholder equity continue total number authorize share plan remain share available future grant plan transfer plan additionally option grant plan expire terminate exercised share common stock reserve option available future grant plan november gilead adopt director plan issuance common stock nonemployee directors pursuant predetermine formula exercise price option grant director plan equal fair value gilead common stock date grant option grant january vest year date grant quarterly percent installment initial option grant january new director vest year date grant equal annual installment annual grant exist director vest year option expire year stockholder approve amendment director plan increase total number authorize share plan remain share available grant plan transfer plan additionally option grant plan expire terminate exercised share common stock reserve option available future grant plan stock plan assume gilead merger nexstar include stock option plan incentive stock plan director option plan collectively nexstar plan option pursuant nexstar plan issue outstanding july convert option purchase gilead common stock result merger remain subject original term condition share available grant future option nexstar plan stock plan assume gilead acquisition net asset triangle include stock option plan separate plan chief executive officer triangle collectively triangle plan option pursuant plan issue outstanding january convert option purchase approximately million share gilead common stock result acquisition remain subject original term condition share available grant future option triangle plan gilead sciences inc note consolidated financial statement continue december stockholder equity continue follow table summarize activity gilead nexstar triangle stock option plan option grant present table exercise price fair value underlie stock grant date share thousand year end december weight weight weight average average average exercise exercise exercise share price share price share price outstanding beginning year grant assume forfeit exercise outstanding end year exercisable end year weight average fair value option grant follow summary gilead option outstanding option exercisable december option thousand option outstanding option exercisable weighted average weight remain average weighted option contractual exercise option average exercise range exercise price outstanding life year price exercisable price total preferred share purchase right plan november adopt preferred share purchase right plan right plan right plan provide distribution prefer stock purchase right dividend share gilead common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase gilead common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price gilead sciences inc note consolidated financial statement continue december stockholder equity continue purchase right purchase right voting privilege attach automatically trade gilead common stock october october board director approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second amendment provide thing increase exercise price right plan extension term right plan october comprehensive income loss comprehensive income loss comprise net income certain change stockholder equity exclude net income exclude item comprehensive income loss include change fair value untriggered effective cash flow hedge change unrealize gain loss availableforsale security change cumulative foreign currency translation account comprehensive income loss year end december include consolidated statement stockholder equity component comprehensive income loss show net relate taxis underlie asset liability hold jurisdiction expect generate future tax benefit liability follow reclassification record connection net realize gain loss sale security cash flow hedge previously include comprehensive income loss thousands year end december net unrealize loss arise year availableforsale security net tax benefit respectively net unrealized gain loss arise year cash flow hedge reclassification adjustment net tax benefit provision respectively comprehensive loss balance accumulate comprehensive income loss net taxis report balance sheet consist follow component thousand december net unrealized loss availableforsale security net unrealize loss cash flow hedge net foreign currency translation gain accumulate comprehensive income loss gilead sciences inc note consolidated financial statement continue december disclosure segment enterprise related information gilead operate business segment primarily focus development commercialization human therapeutic infectious disease product include segment major product viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate collectively hiv product ambisome amphotericin b liposome injection account product sale year end december respectively similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december hiv product viread emtriva truvada total hiv product ambisome hepsera vistide daunoxome total product revenue follow table summarize revenue external customer collaborative partner geographic region revenue attribute country base location customer collaborative partner thousand year end december united states france spain united kingdom italy germany switzerland european country country total revenue gilead sciences inc note consolidated financial statement continue december disclosure segment enterprise relate information continue december net book value property plant equipment million approximately asset locate united states december net book value property plant equipment million approximately asset locate united states follow table summarize revenue large customer distribute drug primarily united states total revenue year end december cardinal health inc amerisourcebergen corp mckesson corp income taxis provision benefit income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer foreign pretax income loss million million million gilead foreign subsidiary generate operating loss reflect cost build commercial infrastructure europe foreign subsidiary investment research development effort unremitte foreign earning consider permanently invest outside united states taxis provide approximately million december residual tax liability amount remit approximately million gilead sciences inc note consolidated financial statement continue december income taxis continue difference provision benefit taxis income compute apply federal statutory income tax rate income loss provision benefit income taxis explain thousands year end december income loss provision benefit income taxis tax federal statutory rate state taxis net federal benefit benefit loss change valuation allowance foreign earning different rate research experimentation credit inprocess research development charge foreign loss different rate provision benefit income taxis tax benefit associate stock option exercise employee stock purchase plan result tax benefit million year end december benefit credit additional paidin capital realize gilead sciences inc note consolidated financial statement continue december income taxis continue deferred income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability december follow thousand december defer tax asset net operating loss carryforward research tax credit carryforward reserve accrual currently deductible depreciation relate capitalize research development expense net valuation allowance total defer tax asset defer tax liability unremitte foreign earning total defer tax liability net defer tax asset valuation allowance decrease million million year end december respectivelywe valuation allowance million million december respectively conclude base standard set forth sfas accounting income taxis likely realize benefit relate deferred tax asset assess need valuation allowance quarter end base available evidence approximately million valuation allowance december relate tax benefit stock option deduction credit additional paidin capital realize december federal net operating loss carryforward approximately million federal net operating loss carryforward expire date utilize addition federal state tax credit carryforward approximately million million respectively expire date utilize utilization net operating loss tax credit carryforward subject annual limitation ownership change limitation provide internal revenue code similar state provision annual limitation result expiration net operating loss credit utilization october american jobs creation act ajca sign law ajca include deduction certain foreign earning repatriate define ajca elect apply provision qualify earning repatriation fiscal start gilead sciences inc note consolidated financial statement continue december income taxis continue evaluation effect repatriation provision expect able complete evaluation congress treasury department provide additional clarify language key element ajca expect complete evaluation potential effect repatriation provision reasonable period time follow publication additional clarify language range possible amount consider repatriation ajca zero million maximum allowable company define ajca relate potential range income tax reasonably estimate december defer compensation plan gilead maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead plan gilead plan employee contribute eligible annual compensation gilead make matching contribution gilead plan contribute employee contribution annual maximum match total matching contribution expense gilead plan million million million gilead maintain defer compensation plan director officer defer compensation income tax purpose internal revenue code plan officer contribute annual salary annual management bonus director contribute annual retainer fee amount defer participant deposit rabbi trust record noncurrent asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share december issue phantom share participant elect distribution date available plan receive defer compensation payment gilead sciences inc note consolidated financial statement continue december quarterly result operation unaudite follow table thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income net income sharebasic net income sharedilute st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income loss net income loss sharebasic net income loss sharedilute quarter gilead record pretax gain million relate warrant eyetech complete initial public offering fourth quarter gilead record expense million connection makewhole payment convertible senior debt holder relation redemption conversion convertible senior debt quarter gilead complete acquisition net asset triangle record charge million purchase inprocess research development quarter gilead reimburse million research development expense result settlement contractual dispute vendor fourth quarter gilead record noncash impairment charge certain longlive asset million addition record income tax benefit million relate reduction valuation allowance certain net defer tax asset september gilead implement twoforone stock split form stock dividend share share amount period present restate reflect stock split gilead sciences inc schedule ii valuation qualifying account balance addition balance begin charge charge end period expense deduction period year end december account receivable allowance inventory reserve valuation allowance defer tax asset year end december account receivable allowance inventory reserve valuation allowance defer tax asset year end december account receivable allowance inventory reserve valuation allowance defer tax asset allowance doubtful account sale return cash discount chargeback